ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

A supplemental biologics license application has been submitted to the FDA for nogapendekin alfa plus Bacillus ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary ...

In terms of financial performance, ImmunityBio reported that its Q1 2025 Anktiva unit sales volume grew by 150% over the unit ...

The shingles vaccine, typically administered to fend off a painful rash, might pack an unexpected benefit by delaying or even preventing dementia. Groundbreaking research from Stanford University ...

IT white papers, webcasts, case studies, and much more - all free to registered TechRepublic members. Hire the right mainframe systems programmer to maintain critical IT infrastructure. Ensure ...

Near Protocol price analysis for March 28 shows that the price rose to the $3.00 mark as bulls found support at $2.50. However, the selling pressure remains high making it difficult to cross the key ...

The Economic Crime Cooperation Division (ECCD) is responsible for the Council of Europe’s cooperation and technical assistance related activities concerning measures against corruption, money ...

It is supplemented by a First additional Protocol on Xenophobia and Racism via computer systems. A Second Additional Protocol has recently been adopted; the Cybercrime Convention Committee (T-CY) ...